TRVN Trevena Inc

Price (delayed)

$0.24

Market cap

$4.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.75

Enterprise value

-$14.5M

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, ...

Highlights
Trevena's gross profit has surged by 145% YoY and by 3.6% QoQ
The EPS has soared by 54% YoY and by 13% from the previous quarter
TRVN's equity has plunged by 91% from the previous quarter
The quick ratio is down by 25% from the previous quarter and by 9% YoY

Key stats

What are the main financial stats of TRVN
Market
Shares outstanding
18.34M
Market cap
$4.4M
Enterprise value
-$14.5M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.62
Earnings
Revenue
$3.14M
EBIT
-$36.12M
EBITDA
-$35.78M
Free cash flow
-$31.6M
Per share
EPS
-$2.75
Free cash flow per share
-$1.48
Book value per share
-$0.97
Revenue per share
$0.15
TBVPS
$1.46
Balance sheet
Total assets
$31.14M
Total liabilities
$45.79M
Debt
$5.19M
Equity
-$14.65M
Working capital
$18.77M
Liquidity
Debt to equity
-0.35
Current ratio
3.6
Quick ratio
3.34
Net debt/EBITDA
0.53
Margins
EBITDA margin
-1,139.8%
Gross margin
48%
Net margin
-1,279%
Operating margin
-1,116.5%
Efficiency
Return on assets
-103.1%
Return on equity
N/A
Return on invested capital
-533%
Return on capital employed
-150.9%
Return on sales
-1,150.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TRVN stock price

How has the Trevena stock price performed over time
Intraday
4.35%
1 week
9.09%
1 month
-40%
1 year
-74.59%
YTD
-66.76%
QTD
9.09%

Financial performance

How have Trevena's revenue and profit performed over time
Revenue
$3.14M
Gross profit
$1.51M
Operating income
-$35.05M
Net income
-$40.15M
Gross margin
48%
Net margin
-1,279%
Trevena's gross profit has surged by 145% YoY and by 3.6% QoQ
TRVN's operating income is up by 30% year-on-year
TRVN's net income is up by 11% year-on-year
The gross margin is up by 3% from the previous quarter

Growth

What is Trevena's growth rate over time

Valuation

What is Trevena stock price valuation
P/E
N/A
P/B
N/A
P/S
1.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.62
The EPS has soared by 54% YoY and by 13% from the previous quarter
TRVN's equity has plunged by 91% from the previous quarter
The stock's price to sales (P/S) is 100% less than its 5-year quarterly average of 718.8 and 49% less than its last 4 quarters average of 3.2

Efficiency

How efficient is Trevena business performance
The ROIC has shrunk by 133% YoY and by 7% QoQ
Trevena's return on assets has decreased by 16% YoY and by 4.2% QoQ

Dividends

What is TRVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TRVN.

Financial health

How did Trevena financials performed over time
TRVN's total assets is 32% less than its total liabilities
The total liabilities has soared by 63% YoY but it has decreased by 5% from the previous quarter
The quick ratio is down by 25% from the previous quarter and by 9% YoY
TRVN's debt is 135% greater than its equity
TRVN's debt to equity has dropped by 158% year-on-year but it has surged by 51% since the previous quarter
TRVN's equity has plunged by 91% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.